Abstract 248P
Background
Carcinoma cervix is a leading cause of cancer in Indian females where 15%–60% of the cases eventually metastasize. This is a retrospective review of outcome of metastatic carcinoma cervix patients treated in Kidwai Memorial institute, Bangalore from 2016-2018.
Methods
We retrospectively analysed our data between October 2016 and September 2018 to identify the cases of metastatic carcinoma cervix and tried to analyse their outcomes with platinum-based chemotherapy.
Results
138 cases of metastatic carcinoma cervix were identified during these 2 years. Median age was 49 years (29-73 years). 27(19.5%) patients were HIV+. 39(28.8%) were upfront metastatic & 99(71.8%) were recurrent metastatic. Most common histology was Squamous cell carcinoma, grade II (50%). Nodal recurrence was seen in 108 (78.2%) patients, with most common being pelvic lymph nodes (69.5%) followed by retroperitoneal lymphadenopathy (36.9%) & supraclavicular lymphadenopathy (19.5%). Distant recurrence seen in 93 patients (67.3%) & most common site was lung (54.3%) followed by liver(45.6%), adrenal(4.3%), bone(6.5%) & ascites(8.6%). Nodal-only recurrence was seen in 45 (32.6%) patients. 129(93.4%) patients received palliative chemotherapy as follows- Paclitaxel/Carboplatin (82.6%), Paclitaxel/Cisplatin (6.5%), Gemcitabine/Carboplatin (2.1%), Paclitaxel/Carboplatin/Bevacizumab (2.1%). Overall response rates were 32.6% (CR-4.3%). Median progression-free survival and overall survival (OS) were 6 months and 13 months, respectively.
Conclusions
Nodal-only metastasis did not show favourable outcome as compared to visceral metastasis. However, disease remains aggressive and poor survival demands further research into newer molecules & regimens.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
249P - Accuracy of endometrial biopsy by Pipelle: A systematic review and meta-analysis
Presenter: Jinhai Gou
Session: Poster display session
Resources:
Abstract
250P - Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities
Presenter: Gonçalo Nogueira da Costa
Session: Poster display session
Resources:
Abstract
251P - A prognostic index model for predicting long-term recurrence of uterine leiomyoma after initial myomectomy in women aged 18-44 years
Presenter: Xiu Ming
Session: Poster display session
Resources:
Abstract
252P - Uterine sarcomas in Qatar: Clinico-pathological characteristics and treatment outcome
Presenter: Ashraf Fadlelseid
Session: Poster display session
Resources:
Abstract
253P - Anti-PD-1-induced reinvigoration of tumour-infiltrating CD8+ T cells in epithelial ovarian cancer patients is correlated with T cell factor-1
Presenter: Junsik Park
Session: Poster display session
Resources:
Abstract
254P - Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)
Presenter: Diar Aziz
Session: Poster display session
Resources:
Abstract
255P - MEX3A is a prognostic biomarker and correlates with RNA splicing and cell proliferation in endometrial cancer by analysis of RNA-seq data
Presenter: Huining Jing
Session: Poster display session
Resources:
Abstract
256P - Lnc-AL445665.1-4 may be involved in the development of multiple uterine leiomyoma through interacting with miR-146b-5p
Presenter: E Yang
Session: Poster display session
Resources:
Abstract
257P - Treatment results of low risk gestational trophoblastic neoplasia (GTN) from a tertiary hospital, Chennai, India
Presenter: Rakesh M. P
Session: Poster display session
Resources:
Abstract
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract